Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy

Keyphrases

• BRCA mutation 100%
• Platinum-based Chemotherapy 100%
• BRCA mutation Carriers 100%
• Chemotherapy Toxicity 100%
• Epithelial Ovarian Cancer 80%
• Non-carriers 60%
• Ovarian Cancer 60%
• Treatment Delay 60%
• Germline BRCA mutation 60%
• Non-associated 40%
• Granulocyte Colony-stimulating Factor (G-CSF) 40%
• Chemotherapy Dose 40%
• Febrile Neutropenia 40%
• Chemotherapy Schedule 40%
• No Significant Difference 20%
• Hemoglobin 20%
• Patient Demographics 20%
• Mutation Carriers 20%
• Implications for Practice 20%
• Neutropenia 20%
• Retrospective Cohort Study 20%
• Increased Vulnerability 20%
• Neutrophil Count 20%
• DNA Damage 20%
• Inclusion Criteria 20%
• Blood Transfusion 20%
• Germline mutation 20%
• Platelet Count 20%
• Thrombocytopenia 20%
• In Care 20%
• Healthy Cells 20%
• Hematologic 20%
• Single Center 20%
• Blood Count 20%
• Toxicity Profile 20%
• Frequent mutation 20%
• Transfusion Requirements 20%
• Bone Marrow Toxicity 20%
• Hematotoxicity 20%
• CA-125 Levels 20%
• Serous Tumor 20%
• Chemotoxicity 20%
• Homologous Recombination Defect 20%

Medicine and Dentistry

• BRCA Mutation 100%
• Krukenberg Tumor 33%
• Ovarian Cancer 25%
• Therapy Delay 25%
• Germ Cell 25%
• Granulocyte Colony Stimulating Factor 16%
• Febrile Neutropenia 16%
• Neutropenia 8%
• Retrospective Cohort Study 8%
• Clinician 8%
• Homologous Recombination 8%
• Neoplasm 8%
• Allele 8%
• Blood Transfusion 8%
• DNA Damage 8%
• Platelet 8%
• Thrombocytopenia 8%
• Patient Population 8%
• Germline Mutation 8%
• CA-125 8%
• Bone Marrow Toxicity 8%
• Neutrophil 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Ovary Carcinoma 50%
• Ovary Cancer 37%
• Granulocyte Colony Stimulating Factor 25%
• Febrile Neutropenia 25%
• Cohort Study 12%
• Neoplasm 12%
• Neutropenia 12%
• Thrombocytopenia 12%
• Bone Marrow Toxicity 12%